---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-23-000043"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:23:30.335357+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q3 net product revenue $40.8M (+60% YoY); narrows FY2023 guidance to $155-160M

## Summary
- Net product revenue $40.8M in Q3, up 60% YoY; 9-month net product revenue $116.2M (+55%).
- Narrowed FY2023 net product revenue guidance to $155-160M from prior range.
- Net loss $13.4M ($0.09/share) vs $9.0M ($0.06/share) in Q3 2022; 9-month net loss improved to $51.1M from $82.1M.
- Patients on LUPKYNIS at Sept 30: ~1,939 (+43% YoY); 436 PSFs added in Q3 (+17%).
- Received $10M milestone from Otsuka for European pricing and reimbursement in three major markets.

## SEC filing metadata
- accession: 0001600620-23-000043
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000043/0001600620-23-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000043/auph-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-23-000043
- JSON: https://secwatch.observer/filing/0001600620-23-000043.json
- Plain text: https://secwatch.observer/filing/0001600620-23-000043.txt

## Key facts
- Earnings Releases
  Aurinia Pharmaceuticals Inc. reported three months ended September 30, 2023 results: revenue $54.5 million.
  - Period: three months ended September 30, 2023
  - Revenue: $54.5 million
  - Result: reported results
  source text: Total net revenue was $54.5 million for the three months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000043/0001600620-23-000043-index.htm
- Earnings Releases
  Aurinia Pharmaceuticals Inc. reported nine months ended September 30, 2023 results: revenue $130.4 million.
  - Period: nine months ended September 30, 2023
  - Revenue: $130.4 million
  - Result: reported results
  source text: Total net revenue was $130.4 million for the nine months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000043/0001600620-23-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.